Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

NCT07714382 | Completed

• 1 other identifier: TNBC-RD-2026-001
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival

Conditions

Triple-Negative Breast Cancer (TNBC)

Keywords

Triple-Negative Breast Cancer (TNBC)

Outcome Measures

Primary Outcomes (1)

• Disease free survival

  Up to 3 years

Interventions

Chemo-radiotherapy alone PROCEDURE

Chemo and radiotherapy before surgery

Not applicable- observational study OTHER

Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult female patients with histologically confirmed triple-negative breast cancer (TNBC) who received neoadjuvant systemic therapy followed by definitive surgery and were treated at the study institution during the study period. Data will be collected retrospectively from medical records to evaluate the association between residual disease after neoadjuvant therapy and survival outcomes.

You may qualify if:

• Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR).
• Complete clinical, pathological, treatment, and follow-up data available in the medical records.

You may not qualify if:

• Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery.
• Patients with incomplete or missing essential clinical, pathological, or follow-up data.
• Patients with a history of another primary malignancy that could affect survival analysis.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag university

Sohag, Egypt

Location

MeSH Terms

Conditions

Triple Negative Breast Neoplasms

Condition Hierarchy (Ancestors)

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor of oncology

Study Record Dates

• First Submitted: July 15, 2026
• First Posted: July 20, 2026
• Study Start: May 1, 2026
• Primary Completion: June 1, 2026
• Study Completion: July 1, 2026
• Last Updated: July 20, 2026

Record last verified: 2026-07

Locations

EG (1)